It was a great pleasure to meet with Susan Swindells (University of Nebraska, Omaha, NE, USA) to discuss the FLAIR and ATLAS study results, following the recent FDA approval of cabotegravir + rilpivirine for the treatment of HIV-1.
Questions:
- What are the advantages of Cabenuva (cabotegravir + rilpivirine) compared to current treatment regimens?
- Could you give us a brief overview of the FLAIR and ATLAS studies?
- What did the findings of the FLAIR and ATLAS studies teach us about the efficacy of the treatment regimen?
- What were the study findings in terms of patient preference data?
- Which patients are most likely to benefit from this regimen and in whom is it contraindicated?
Disclosures: Susan Swindells’ institution has received research grants from ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media.
